Strides launches Hep C drug in the country

Strides Arcolab announced the launch of generic drug Sofosbuvir in India under the brand name 'Virso'


(Photo Courtesy:

In September 2014, Strides entered into a licensing agreement with Gilead Sciences, to bring hepatitis C cure to 91 developing countries.

The product will be available to Indian patients shortly.

Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for hepatitis C treatment and represents a paradigm shift in the existing hepatitis C management.

The high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of Sofosbuvir makes it a breakthrough drug in hepatitis C treatment.

This drug in combination therapy has shown to have high cure rates of around 90 percent.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email